Curcumin in Osteoarthritis: Meta-Analysis on Pain Reduction

⚠️ IMPORTANT LEGAL NOTICE

These scientific studies are for informational purposes only.

The presented research results are NOT approved Health Claims under EU Regulation (EC) No 1924/2006. For product advertising, only Health Claims officially approved by EFSA may be used.

Non-approved Health Claims are legally inadmissible and may lead to warnings.

✅ Check approved claims: [EU Health Claims Register](https://ec.europa.eu/food/safety/labelling_nutrition/claims/register/public/)

---

## Summary

A meta-analysis by Zeng L et al. from 2023 investigates the efficacy of curcumin in osteoarthritis and was published in Frontiers in Pharmacology.

Study Background

This systematic review analyzes randomized controlled trials on the analgesic and anti-inflammatory effects of curcumin in osteoarthritis patients.

Key Findings

The meta-analysis shows: - Significant pain reduction: WOMAC score improved by 25-30% - Improvement in joint function: Mobility significantly increased - Dosage: 1000-1500mg curcumin per day - Bioavailability: Optimized with piperine or phospholipids

Methodology

As a meta-analysis, this work combines data from 15 randomized controlled trials with over 1800 patients.

Practical Relevance for Dietary Supplement Manufacturers

These research results are relevant for: - Product development: Curcumin with enhanced bioavailability - Study results: The research shows certain effects (no approved claims) - Dosage: 1000-1500mg standardized extract - Combination: Synergies with Boswellia or MSM

Source

The full study is freely available on Europe PMC.

Authors: Zeng L, Yu G, Hao W, Yang K, Chen H Year: 2023 Journal: Frontiers in Pharmacology PMCID: PMC10130834 PMID: 37153777

---

*Note: This summary is for informational purposes. The presented study results are not approved Health Claims. For detailed information, please consult the original source.*